1. Home
  2. BRAF (gene)
  Subject:

BRAF (gene)   New Search

View on DBpedia    View on Wikipedia
Top related subjects:
 Melanoma Colorectal cancer KRAS V600E Syndrome Neuroblastoma RAS viral oncogene homolog Metastasis Immunohistochemistry Gene Chemotherapy BRAF (gene) Cancer immunotherapy Protein Colonoscopy Adenocarcinoma P53 Thyroid cancer Microsatellite Lymph node Obesity Hypertension Phenotype Polymerase chain reaction Carcinoma Breast cancer Western blot Messenger RNA DNA Acid Radiation therapy Neoadjuvant therapy
RELATED SUBJECTS:
The publications listed also have these subjects
Melanoma  25 times
Colorectal cancer  9 times
KRAS  8 times
Syndrome  7 times
Metastasis  7 times
Immunohistochemistry  7 times
Gene  7 times
Chemotherapy  7 times
Carcinoma  7 times
Mutation  6 times
DNA sequencing  6 times
Protein  5 times
Progression-free survival  5 times
Mitogen-activated protein kinase  5 times
Kinase  5 times
Exon  5 times
Cancer immunotherapy  5 times
Targeted therapy  4 times
Programmed cell death protein 1  4 times
Phenotype  4 times
P53  4 times
Microsatellite instability  4 times
MLH1  4 times
Lymph node  4 times
Immune checkpoint  4 times
Enzyme inhibitor  4 times
DNA  4 times
Skin  3 times
Polymerase chain reaction  3 times
P110α  3 times
Molecular biology  3 times
Microsatellite  3 times
MSH6  3 times
MSH2  3 times
MAPK/ERK pathway  3 times
MAP2K1  3 times
Disease  3 times
CpG site  3 times
CTLA-4  3 times
C-Raf  3 times
Beta-catenin  3 times
Apoptosis  3 times
Antibody  3 times
Tyrosine kinase  2 times
Thyroid cancer  2 times
The Cancer Genome Atlas  2 times
Small interfering RNA  2 times
Skin cancer  2 times
Protein kinase  2 times
Prostaglandin-endoperoxide synthase 2  2 times
Prime Time Entertainment Network  2 times
Pharmacokinetics  2 times
Papillary thyroid cancer  2 times
Oncogene  2 times
Multivariate analysis  2 times
Metabolism  2 times
Messenger RNA  2 times
MAPK3  2 times
Immunotherapy  2 times
Hair loss  2 times
Growth factor  2 times
Glioblastoma multiforme  2 times
Estrogen receptor  2 times
DNA mismatch repair  2 times
Confidence interval  2 times
ClinicalTrials.gov  2 times
Cisplatin  2 times
Carboxylic acid  2 times
Biopsy  2 times
Bevacizumab  2 times
Arthralgia  2 times
Anaplastic lymphoma kinase  2 times
Adenocarcinoma  2 times
Wireless access point  1 time
Western blot  1 time
Vincristine  1 time
Valine  1 time
Unravel  1 time
Ubiquitin ligase  1 time
Trastuzumab  1 time
Thrombocytopenia  1 time
Threonine  1 time
Thalassemia  1 time
Telomere  1 time
Telomerase reverse transcriptase  1 time
T-cell receptor  1 time
Subtyping  1 time
Sorafenib  1 time
Sirolimus  1 time
Shortness of breath  1 time
Serine  1 time
Secondary metabolite  1 time
Scoliosis  1 time
Sanger sequencing  1 time
Rituximab  1 time
Response surface methodology  1 time
Reflex  1 time
Reactive oxygen species  1 time
Radiation therapy  1 time
Questionnaire  1 time
Pyrosequencing  1 time
PubMed  1 time
Protein tyrosine phosphatase  1 time
Prednisone  1 time
Precision medicine  1 time
Polymerase  1 time
Phosphorylation  1 time
Phosphoinositide 3-kinase  1 time
Performance status  1 time
Oxaliplatin  1 time
Norwegian language  1 time
Non-small-cell lung carcinoma  1 time
Neoplasm  1 time
Neoadjuvant therapy  1 time
Munhwa Broadcasting Corporation  1 time
Multiplexing  1 time
Monoclonal antibody  1 time
Mitochondrion  1 time
Mechanistic target of rapamycin  1 time
Magnetic resonance imaging  1 time
MCF-7  1 time
Lymphoma  1 time
Lymphadenopathy  1 time
Luminex Corporation  1 time
Logistic regression  1 time
Library  1 time
Leukopenia  1 time
Leucine  1 time
Israel  1 time
Isocitric acid  1 time
Irinotecan  1 time
Ipilimumab  1 time
Ion exchange  1 time
Intracranial hemorrhage  1 time
Immunoglobulin therapy  1 time
Illumina dye sequencing  1 time
Idiopathic pulmonary fibrosis  1 time
IDH1  1 time
IC50  1 time
Hypertension  1 time
Hydrogen ion  1 time
House mouse  1 time
Histopathology  1 time
Halogen  1 time
Golgi apparatus  1 time
Glycosylation  1 time
Glioma  1 time
Genetic counseling  1 time
Genetic code  1 time
GTPase  1 time
Fluorouracil  1 time
Fluorescence  1 time
Fibrosis  1 time
Fibroblast growth factor  1 time
Fever  1 time
FOXP3  1 time
Extracellular signal–regulated kinases  1 time
Everolimus  1 time
European Medicines Agency  1 time
Etoposide  1 time
Estrogen  1 time
Epigenetics  1 time
Ependyma  1 time
Enzyme  1 time
Endoscopy  1 time
Endocrine system  1 time
Electronic health record  1 time
Electroencephalography  1 time
Ejection fraction  1 time
Dysplasia  1 time
Drug interaction  1 time
Dermatitis  1 time
DNA microarray  1 time
DNA methylation  1 time
Cytopathology  1 time
Cyclophosphamide  1 time
Cutaneous condition  1 time
Corticosteroid  1 time
Confocal microscopy  1 time
Colonoscopy  1 time
Colitis  1 time
Cofactor (biochemistry)  1 time
Clinical trial  1 time
Chromatin  1 time
Chain reaction  1 time
Cell surface receptor  1 time
Celecoxib  1 time
Catenin  1 time
Catalysis  1 time
Catabolism  1 time
Cardiomyopathy  1 time
Carboplatin  1 time
CT scan  1 time
Breast cancer  1 time
Bone marrow examination  1 time
Bone  1 time
Blood plasma  1 time
Astrocytoma  1 time
Antigen  1 time
Anorexia nervosa  1 time
American Joint Committee on Cancer  1 time
Allele  1 time
Adjuvant therapy  1 time
Adjuvant  1 time
Acid  1 time
18 Months  1 time

Publications tagged with this subject: 49

Note: Top 50 publications shown only. Open an item panel to view more info


1. Constitutional mismatch repair deficiency and Lynch syndrome among consecutive Arab Bedouins with colorectal cancer in Israel

2. Molecular Stratification of Colorectal Cancer: Moving from the Laboratory to Clinical Practice

3. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells

4. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

5. Associations of red and processed meat intake with major molecular pathological features of colorectal cancer

6. Next-Generation Sequencing to Guide Treatment of Advanced Melanoma

7. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data

8. Small bowel adenocarcinoma complicating Crohn’s disease: a single-centre experience emphasizing the importance of screening for dysplasia

9. Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma

10. Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients

11. MITF suppression by CH5552074 inhibits cell growth in melanoma cells

12. The landscape of BRAF transcript and protein variants in human cancer

13. Computed determination of the in vitro optimal chemocombinations of sphaeropsidin A with chemotherapeutic agents to combat melanomas

14. Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma

15. Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study

16. Crosstalk signaling in targeted melanoma therapy

17. Assessment of BRAFV600E mutation in pulmonary Langerhans cell histiocytosis in tissue biopsies and bronchoalveolar lavages by droplet digital polymerase chain reaction

18. Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses

19. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

20. A case report of ascending colon adenosquamous carcinoma with BRAF V600E mutation

21. Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism

22. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter s

23. Synchronous and Metastatic Papillary and Follicular Thyroid Carcinomas with Unique Molecular Signatures

24. The undifferentiated carcinoma that became a melanoma: Re-biopsy of a cancer of an unknown primary site: a case report

25. Current applications of molecular pathology in colorectal carcinoma

26. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors

27. Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas

28. Clinical responses of patients with diffuse leptomeningeal glioneuronal tumors to chemotherapy

29. Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months

30. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells

31. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond

32. BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma

33. Integrating Genomics into Drug Discovery and Development: Challenges and Aspirations

34. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases

35. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy

36. Success of referral to genetic counseling after positive lynch syndrome screening test

37. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma

38. Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report

39. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care

40. Role of key genetic mutations on increasing migration of brain cancer cells through confinement

41. Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

42. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients

43. RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers

44. Targeted Therapies for Melanoma Brain Metastases

45. Comprehensive genomic profiling of malignant phyllodes tumors of the breast

46. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M

47. Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency

48. BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?

49. Design, synthesis and biological evaluation of phenylpicolinamide sorafenib derivatives as antitumor agents


Questions?

Drop us a message.